{"schema_version":"secwatch.filing_event.v1","accession":"0001671927-26-000020","form_type":"8-K","ticker":"IMCR","cik":"0001671927","company_name":"Immunocore Holdings plc","filed_at":"2026-08-06T11:01:22+00:00","discovered_at":"2026-08-06T11:05:00.260856+00:00","generated_at":"2026-08-06T11:06:13.085298+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Immunocore Q2 2026: KIMMTRAK rev $115.9M (+18% YoY); net loss $0.8M; TEBE-AM enrollment nearing target","bullets":["KIMMTRAK net revenue $115.9M in Q2 2026, up 18% YoY; US sales $74.9M, Europe $34.1M, international $6.9M.","Net loss narrowed to $0.8M ($0.02 loss per share) from $10.3M loss in Q2 2025; H1 2026 net income $12.2M.","Phase 3 TEBE-AM trial for 2L+ advanced cutaneous melanoma enrollment nearing 540 patients; topline data possible end of 2026.","Five-year OS data: KIMMTRAK OS rate 16% vs 8% control; median OS 21.6 vs 16.9 months (HR 0.67).","Brenetafusp monotherapy in heavily pretreated advanced melanoma: ORR 17%, DCR 67% at 160 mcg; supports Phase 3 PRISM-MEL-301 dose."],"urls":{"canonical":"https://secwatch.observer/filing/0001671927-26-000020","json":"https://secwatch.observer/filing/0001671927-26-000020.json","markdown":"https://secwatch.observer/filing/0001671927-26-000020.md","text":"https://secwatch.observer/filing/0001671927-26-000020.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671927/000167192726000020/0001671927-26-000020-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671927/000167192726000020/imcr-20260806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T11:06:13.085298+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}